However, the same system can be used to evaluate other MRT agents, such as 177Lu-PSMA, which is increasingly applied for the treatment of prostate cancer, long-range β-emitting radiopharmaceuticals based on 90Y or 131I, or targeted α-emitter therapy based on 225Ac or 231Bi, given their propensity to cause complex DNA damage and abundant γH2AX signals (37). The gene discussed is FOLH1; the disease is Familial prostate cancer.